What is Curevo Vaccine?
Curevo Vaccine is a specialized clinical-stage biotech company dedicated to the development of next-generation non-mRNA, adjuvanted subunit vaccines. The company's primary focus is on enhancing the efficacy and accessibility of vaccines for patients with significant medical needs, including immunocompromised populations. Its lead candidate, amezosvatein, represents a strategic effort to mitigate vaccine hesitancy by providing better-tolerated alternatives to existing market solutions. By concentrating on specific, high-impact medical targets, Curevo Vaccine maintains a lean and efficient development model that prioritizes rapid clinical progression and high-quality therapeutic outcomes.
How much funding has Curevo Vaccine raised?
Curevo Vaccine has raised a total of $196M across 3 funding rounds:
Series A
$60M
Other Financing Round
$26M
Other Financing Round
$110M
Series A (2022): $60M with participation from EN Investment, GC Pharma, Janus Henderson Investors, Adjuvant Capital, and RA Capital Management
Other Financing Round (2022): $26M led by Janus Henderson Investors, RA Capital Management, GC Biopharma, and Adjuvant Capital
Other Financing Round (2025): $110M supported by Medicxi, Adjuvant Capital, RA Capital Management, HBM Healthcare Investments, GC Biopharma, Janus Henderson Investors, Sanofi Ventures, and OrbiMed
Key Investors in Curevo Vaccine
OrbiMed
OrbiMed is a specialized healthcare investment firm managing capital across biopharmaceuticals and medical devices, known for its hands-on approach to supporting companies through various stages of development.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in life science companies, utilizing its internal TechAtlas think tank to support clinical innovation.
Adjuvant Capital
Adjuvant Capital is a venture capital firm dedicated to financing life science technologies that address high-burden public health challenges, emphasizing both social and financial returns.
What's next for Curevo Vaccine?
With the successful closure of this major strategic investment, Curevo Vaccine is well-positioned to advance its clinical programs and scale its operational capabilities. The company is expected to leverage this capital to further validate the safety and efficacy of amezosvatein, potentially setting the stage for future regulatory submissions and commercialization strategies. As the firm continues to navigate the complex landscape of vaccine development, the focus will remain on optimizing its subunit technology platform to address broader infectious disease challenges. The ongoing support from its diverse investor base provides the necessary financial runway to sustain long-term innovation and maintain its competitive edge in the global biopharmaceutical market.
See full Curevo Vaccine company page
